Evidence map›Paper›PMID 34830797›Full record

ArticleCancers2021

Phenotypic Consequences of

Kathleen I Pishas, Karla J Cowley, Ahwan Pandey, Therese Hoang, Jessica A Beach, Jennii Luu, Robert Vary, Lorey K Smith, Carolyn E Shembrey, Nineveh Rashoo and 8 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 2 countries.

Kathleen I PishasPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Karla J CowleyVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Ahwan PandeyPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0003-2238-1054
Therese HoangPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Jessica A BeachPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Jennii LuuVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Robert VaryVictorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Lorey K SmithPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Carolyn E ShembreyPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Nineveh RashooPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Madelynne O WhitePeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Kaylene J SimpsonThe Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC 3010, Australia.
Andrea BildDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
Jason I GriffithsDepartment of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, CA 91010, USA.
Dane CheasleyPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Ian CampbellPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
David D L BowtellPeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.
Elizabeth L ChristiePeter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.ORCID 0000-0002-9959-7024
Peter MacCallum Cancer Centre · AUThe University of Melbourne · AUCity Of Hope National Medical Center · US

Funding

Project 2: Targeting Cooperative Phenotypes Common in Spatial HeterogeneityU54CA209978 · NCI · UNIVERSITY OF UTAH · PI BILD, ANDREA HOPE · 2017 to 2021
$10.5M
Cancer Council Victoria APP1184894Cancer Systems Biology Center U54 grant U54CA209978National Health and Medical Research Council APP1124309NHMRC APP1161198NHMRC CJ Martin Overseas Biomedical Fellowship APP1111032Therapeutic Innovation Australia Pipeline Accelerator GrantUS National Cancer Institute U54 U54CA209978Victorian Cancer Agency ECSG15012
6 · The paper itself

Abstract

Despite high response rates to initial chemotherapy, the majority of women diagnosed with High-Grade Serous Ovarian Cancer (HGSOC) ultimately develop drug resistance within 1-2 years of treatment. We previously identified the most common mechanism of acquired resistance in HGSOC to date, transcriptional fusions involving the ATP-binding cassette (ABC) transporter

Indexed as

ABCB1drug resistancehigh-grade serous ovarian cancerhigh-throughput drug screening

Identifiers

PMID34830797
PMCPMC8616176
OpenAlexW3212915294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.